Biotech activity in the US equity capital markets is showing renewed signs of life following a multiyear drought. Molecular diagnostics firm BillionToOne’s successful initial public offering on the Nasdaq is seen as a possible marker of a tentative reopening for the sector, but capital-markets practitioners caution that a true rebound remains contingent on macro stability heading into 2026. Kaush Amin, managing director and head of private markets investing at US Bank, said this area of life sciences has endured a protracted period of volatility stemming from shifting reimbursement policies and political noise, which may finally be approaching a bottom.
Read the full article: Biotech IPO Window Shows Green Shoots, with Momentum Building for 2026 //
Source: https://ionanalytics.com/insights/mergermarket/biotech-ipo-window-shows-green-shoots-with-momentum-building-for-2026/